Xcovery Announces the Appointment of Giovanni Selvaggi as Chief Executive Officer
18 Mar 2021
PALM BEACH GARDENS, Fla.--(BUSINESS WIRE)-- Xcovery Holdings, Inc., an oncology focused bio-pharmaceutical company, today announced that Giovanni Selvaggi, M.D., has been appointed as the Chief Executive Officer (CEO), replacing Li Mao, M.D., who is leaving for personal reasons. Dr. Selvaggi will also continue as Xcovery’s Chief Medical Officer (CMO).
This press release features multimedia. View the full release here:
Dr. Giovanni Selvaggi (Photo: Business Wire)
“Giovanni is the right leader for Xcovery,” said Lieming Ding, M.D., Chairman of the Board. “For the past two years, Giovanni has been successfully driving forward the ensartinib and vorolanib clinical programs as the company CMO. His proven leadership and industry expertise will be crucial for the regulatory and commercial success of our drugs.”
“Xcovery is at a critical yet very exciting juncture,” stated Dr. Selvaggi. “I’m ready to take on the new challenges and responsibilities. We have a very good late stage clinical program in ensartinib, which has the potential to be the best-in-class treatment for ALK+ NSCLCALK+ NSCLC patients. We are taking the drug over the finish line so NSCLC patients can have a new option to fight the disease.”
Dr. Selvaggi received his medical degree at the University of Torino Medical School in 1992 and served as physician of Thoracic Oncology in Torino over a span of 16 years. Dr. Selvaggi joined the pharmaceutical industry in 2010 as a medical director at GlaxoSmithKline. He then played an instrumental role in the successful development and registration of ceritinib (Zykadia) at Novartis. Dr. Selvaggi was also at Bristol-Myers Squibb as Program Lead in different thoracic malignancies with a focus on SCLC. From March 2019, Dr. Selvaggi has been the Chief Medical Officer at Xcovery.
About Xcovery
Xcovery is a biopharmaceutical company working to improve the lives of patients with cancer by discovering medicines to fight advanced tumors. Xcovery is developing a pipeline of oncology therapies to target a wide range of advanced tumors. For more information, visit .
Forward‐Looking Statements
This press release contains forward‐looking statements that are based on company management’s current beliefs and expectations and are subject to currently unknown information, risks and circumstances and actual results may vary from what is being currently projected.
Organizations
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.